Ozempic vs Rybelsus
the same molecule (semaglutide), injectable vs oral, both reviewed for type 2 diabetes
What the regulatory reviews say
Ozempic (semaglutide) is an injectable medication approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. Rybelsus (semaglutide) is an oral medication approved for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
The regulatory reviews for Ozempic highlighted its efficacy in glycemic control and cardiovascular risk reduction. Rybelsus's review focused on its ability to improve glycemic control. The trials for each drug were designed independently, with distinct populations, comparators, and timepoints. Therefore, the reported figures are not directly comparable, and neither drug is presented as superior to the other based on these separate trial outcomes.
Each drug's own results — cited
| Ozempic | Rybelsus | |
|---|---|---|
| Elimination Half-life | 155 Mean t½ in subjects with T2D (hours) Novo Nordisk A S — Ozempic EMA EPAR public assessment report, p.37 | 1 week Elimination half-life of semaglutide NOVO — Semaglutide FDA Review (NDA213051, ORIG 1, 2019), p.10 |
Explore the full evidence
Every cited finding behind both drugs is in the Metabolic research library →
Figures are as stated in the cited regulatory review documents. Educational reference only — not medical or investment advice.